CTRI/2017/07/008976已完成3 期
Clinical Trial Protocol for Evaluation of Immunogenicity and Safety of Rabies Vaccine Human (Cell Culture) I.P. in post exposure subjects
Biomed Private Limited0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Subject is bitten by suspect rabid animal and having either category II or III exposure as assessed by history,physical examination and clinical judgment of the investigator.
- •2.Subject is of age group (2 to 65)years.
- •3.Subject is of Indian origin and will remain in the study area for the length of the trial.
- •4.Subject should accept written and inform consent.
- •5.Subject is aware of full information regarding the vaccine and clinical trial.
排除标准
- •1.History of allergy or hypersensitivity to any component of the vaccine.
- •2.History of Rabies immunization.
- •3.Person participating in any other study at the same time or during the past three months.
- •4.Surgery planned during the study period.
- •5.Person known to be HIV positive.
- •6. Pregnant women.
- •7.Infants and children <=2 years of age.
研究者
相似试验
招募中
不适用
HIV VACCINE BOOSTING STUDY FOR FORMER PARTICIPANTS OF HVTN 205 STUDY-Z206 Contact with and exposure to human immunodeficiency virus [HIV]Contact with and exposure to human immunodeficiency virus [HIV]Z206PER-046-16Instituto Nacional de Alergias y Enfermedades Infecciosas (NIAID). EEUU,10
进行中（未招募）
1 期
Immunogenicity, Tolerability, and Manufacturing Consistency study of a Multivalent HPV, VLP vaccinePrevention of cervical, vulvar, and vaginal cancers and related precancers, externalgenital lesions, Pap test abnormalities, and persistent infection caused by humanpapillomavirus (HPV) Types 6, 11, 16, 18, 31, 33, 45, 52, and 58.MedDRA version: 20.1Level: LLTClassification code 10063001Term: Human papilloma virus infectionSystem Organ Class: 100000004862EUCTR2009-011617-25-BEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co.,2,000
已完成
3 期
A Study of V503 (Multivalent HPV Vaccine) in Preadolescents and Adolescents. This study will evaluate the immunogenicity and tolerability of V503 in preadolescent and adolescent subjects between 9 and 15 years old and demonstrate the consistency of the manufactured vaccine through assessment of 3 different final manufacturing process lots of V503.CTRI/2009/091/000767Merck Sharp and Dohme2,800
进行中（未招募）
3 期
This study will evaluate the immunogenicity and tolerability of V503 ipreadolescent and adolescent subjects between 9 and 15 years old andemonstrate the consistency of the manufactured vaccine throughassessment of 3 different final manufacturing process lots of V503.CTRI/2013/09/004012Merck Sharp and Dohme2,800
进行中（未招募）
1 期
A Phase III Clinical Trial to Study the Immunogenicity, Tolerability, and Manufacturing Consistency of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (9 to 15 year olds) with a Comparison to Young Women (16 to 26 year olds)Cervical CancersVulvar CancerVaginal CancerGenital LesionsPAP Test AbnormalitiesHPV InfectionsMedDRA version: 20.1Level: LLTClassification code 10063001Term: Human papilloma virus infectionSystem Organ Class: 100000004862EUCTR2009-011617-25-Outside-EU/EEAMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.